白介素17与结直肠癌

Interleukin-17 and Colorectal Cancer

结直肠癌是世界范围内的高发癌症,其发病机理尚不明确。大量研究数据表明,基因突变、表观遗传学的改变、饮食习惯以及生活方式等均是结直肠癌发生发展的高危因素。目前,普遍认为慢性炎症在肿瘤的发生发展中起重要作用。白介素17主要由T细胞的亚型Th17细胞分泌产生,能够促进肿瘤相关性炎症,使肿瘤细胞逃避免疫监控。已在胃癌、宫颈癌、食管癌、非小细胞肺癌、肝细胞肝癌、卵巢癌、黑色素瘤、淋巴瘤、乳腺癌、前列腺癌、结直肠癌等多种恶性肿瘤中发现白介素17呈高表达。现有研究表明,白介素17与肠炎和结直肠癌的发生发展密切相关。尽管尚存在争议,多数学者认为白介素17在结直肠癌的发生发展中起促进作用。本文将近年来关于IL-17在结直肠癌的发生发展中的作用以及其与结直肠癌的预后的研究成果进行总结。

Colorectal cancer（CRC） is one of the commonest cancers worldwide, and the mechanism of disease progression remains unknown. A large body of evidence indicates that genetic mutations, epigenetic changes, diet, and lifestyle are key risk factors for CRC initiation and progression. It is widely accepted that chronic inflammation plays an important role in cancer. Interleukin-17（IL-17）,produced by a T cell subset named ＂Th17＂, can promote cancer-elicited inflammation and prevent cancer cells from immune surveillance. Mounting evidence indicates that IL-17 is overexpressed in different cancer, including gastric cancer, cervical carcinoma,esophageal cancer, non-small-cell lung carcinoma, hepatocellular carcinoma, ovarian cancer, melanoma, lymphoma, breast cancer and prostate cancer, as well as CRC. IL-17 has been linked to intestinal inflammation and CRC development. Despite controversy, IL-17 is generally considered to be a promoter in CRC initiation and progression. In this review, we devote to summarize the current progress regarding the role of IL-17 in tumor initiation and progression, as well as the prognostic value in CRC.